Correction: Dueñas Et Al. Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals

cancers

Correction Correction: Dueñas et al. Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals. Cancers 2020, 12, 3419

Nuria Dueñas 1,2,† , Matilde Navarro 1,2,3,†, Àlex Teulé 1 , Ares Solanes 3,Mònica Salinas 1,2,Sílvia Iglesias 1,2, Elisabet Munté 1, Jordi Ponce 4 , Jordi Guardiola 5 , Esther Kreisler 6, Elvira Carballas 7, Marta Cuadrado 8, Xavier Matias-Guiu 9, Napoleón de la Ossa 10,11 , Joan Lop 12 , Conxi Lázaro 1,2, Gabriel Capellá 1,2 , Marta Pineda 1,2,‡ and Joan Brunet 1,2,13,*,‡

1 Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain; [email protected] (N.D.); [email protected] (M.N.); [email protected] (À.T.); [email protected] (M.S.); [email protected] (S.I.); [email protected] (E.M.); [email protected] (C.L.); [email protected] (G.C.); [email protected] (M.P.) 2 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain 3 Hereditary Cancer Program, Catalan Institute of Oncology, 08916 Badalona, Barcelona, Spain; [email protected] 4 Department of Gynecology, Bellvitge University Hospital, Hospitalet de Llobregat, 08908 Barcelona, Spain; [email protected] 5 Department of Gastroenterology, Bellvitge University Hospital, Hospitalet de Llobregat, 08908 Barcelona, Spain; [email protected] 6 Department of General Surgery, Bellvitge University Hospital, Hospitalet de Llobregat, Citation: Dueñas, N.; Navarro, M.; 08908 Barcelona, Spain; [email protected] Teulé, À.; Solanes, A.; Salinas, M.; 7 Department of Gynecology, Trias i Pujol University Hospital, 08916 Badalona, Barcelona, Spain; Iglesias, S.; Munté, E.; Ponce, J.; [email protected] Guardiola, J.; Kreisler, E.; et al. 8 Department of General Surgery, Trias i Pujol University Hospital, 08916 Badalona, Barcelona, Spain; Correction: Dueñas, N., et al. [email protected] 9 Assessing Effectiveness of Colonic Department of Pathology, Bellvitge University Hospital, Hospitalet de Llobregat, 08908 Barcelona, Spain; and Gynecological Risk Reducing fjmatiasguiu.lleida [email protected] 10 Department of Pathology, Trias i Pujol University Hospital, 08916 Badalona, Barcelona, Spain; Surgery in Lynch Syndrome [email protected] Individuals. Cancers 2020, 12, 3419. 11 Department of Pathology, Hospital General de Catalunya—Grupo Quironsalud, 08203 Barcelona, Spain Cancers 2021, 13, 3104. https:// 12 Department of Pathology, Hospital del Mar Institute for Medical Research, 08003 Barcelona, Spain; doi.org/10.3390/cancers13133104 [email protected] 13 Hereditary Cancer Program, Catalan Institute of Oncology-IDBIGI, 17007 Girona, Spain Received: 22 March 2021 * Correspondence: [email protected]; Tel.: +34-93-260-7959 Accepted: 31 May 2021 † These authors contributed equally to this work. Published: 22 June 2021 ‡ These authors contributed equally to this work.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affil- In the original article, there was a mistake in Figure 3 as published [1]. The image iations. presented corresponded to endometrial cancer-specific mortality cumulative incidence, instead of the figure referred to in the title (all-cause mortality cumulative incidence). The corrected Figure3 appears below: The study carried out is an analysis of cumulative incidence of mortality and not Copyright: © 2021 by the authors. an analysis of overall survival, as explicitly reported in the methodology section Licensee MDPI, Basel, Switzerland. (Sections 4.3 and 4.4). Our study, like other retrospective studies could suffer from bias. This article is an open access article For that reason, we did a balanced discussion of the strengths and weaknesses of our work distributed under the terms and in the Discussion section (paragraphs 11, 13 and 14) discussing limitations of retrospective conditions of the Creative Commons studies, possible cohort effects, selection of patients based on clinical characteristics, etc.). Attribution (CC BY) license (https:// Moreover, to facilitate the reader’s understanding of the text, we would like to refine the creativecommons.org/licenses/by/ conclusions of our work as follows, making them more precise: 4.0/).

Cancers 2021, 13, 3104. https://doi.org/10.3390/cancers13133104 https://www.mdpi.com/journal/cancers Cancers 2021, 13, 3104 2 of 2 Cancers 2021, 13, x FOR PEER REVIEW 2 of 2

FigureFigure 3.3. All-causeAll-cause mortalitymortality cumulativecumulative incidenceincidence inin femalesfemales withwith LynchLynch syndromesyndrome comparingcomparing risk risk reducing gynecological surgery and non-risk reducing gynecological surgery: All-cause mortality reducing gynecological surgery and non-risk reducing gynecological surgery: All-cause mortality cumulative incidence was 0.0% for risk reducing gynecological surgery vs. 52.7% for non-risk re- cumulative incidence was 0.0% for risk reducing gynecological surgery vs. 52.7% for non-risk ducing gynecological surgery (p = not assessable). reducing gynecological surgery (p = not assessable). The study carried out is an analysis of cumulative incidence of mortality and not an “In conclusion, this study confirms that colonic and gynecological risk reducing surg- eriesanalysis are effectiveof overall at survival, decreasing as theexplicitly incidence reported of metachronous in the methodology colorectal section and gynecological (Sections 4.3 cancerand 4.4). in LynchOur study, syndrome like other (LS) retrospective patients. This studies benefit could was seensuffer in from all LS bias. subjects; For that however, reason, cautionwe did isa balanced still needed discussion for MSH6 of andthe strengthPMS2 pathogenics and weaknesses variant of carriers. our work Also, in ourthe resultsDiscus- pointsion section to a reduction (paragraphs in the 11, endometrial 13 and 14) discussing and ovarian limitations cancer-specific of retrospective mortality studies, cumulative pos- incidencesible cohort in femaleseffects, withselection LS that of patients undergo base riskd reducing on clinical gynecological characteristics, surgery. etc.). Differences Moreover, into all-causefacilitate mortalitythe reader’s cumulative understanding incidence of th shoulde text, we be confirmedwould like in to prospective refine the conclusions analyses.” of ourThe work authors as follows, apologize making for them any inconvenience. more precise: All the authors have checked and agreed“In with conclusion, the corrected this study paper confirms content. that The co originallonic and article gynecological has been updated. risk reducing sur- geries are effective at decreasing the incidence of metachronous colorectal and gynecolog- Conflictsical cancer of Interest:in LynchThe syndrome authors declare (LS) patients. no conflict This of interest.benefit was seen in all LS subjects; however, caution is still needed for MSH6 and PMS2 pathogenic variant carriers. Also, our Reference results point to a reduction in the endometrial and ovarian cancer-specific mortality cu- 1. Dueñas, N.; Navarro, M.; Teulmulativeé, À.; Solanes, incidence A.; Salinas,in females M.; Iglesias,with LS S.;that Munt undergoé, E.; Ponce, risk reducing J.; Guardiola, gynecological J.; Kreisler, surgery. E.; et al. Assessing Effectiveness of ColonicDifferences and Gynecological in all-cause mortality Risk Reducing cumulative Surgery incidence in Lynch Syndrome should be Individuals. confirmedCancers in prospec-2020, 12, 3419. [CrossRef][PubMedtive] analyses.” The authors apologize for any inconvenience. All the authors have checked and agreed with the corrected paper content. The original article has been updated.

Conflicts of Interest: The authors declare no conflict of interest.

Reference 1. Dueñas, N.; Navarro, M.; Teulé, À.; Solanes, A.; Salinas, M.; Iglesias, S.; Munté, E.; Ponce, J.; Guardiola, J.; Kreis- ler, E.; et al. Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals. Cancers 2020, 12, 3419, doi:10.3390/cancers12113419.